Compare Charles River Laboratories International, Inc. with Similar Stocks
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
20.46%
0%
20.46%
6 Months
51.39%
0%
51.39%
1 Year
33.54%
0%
33.54%
2 Years
6.95%
0%
6.95%
3 Years
-6.74%
0%
-6.74%
4 Years
-30.15%
0%
-30.15%
5 Years
-19.37%
0%
-19.37%
Charles River Laboratories International, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.95%
EBIT Growth (5y)
3.27%
EBIT to Interest (avg)
5.81
Debt to EBITDA (avg)
2.49
Net Debt to Equity (avg)
0.71
Sales to Capital Employed (avg)
0.69
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
11.49%
ROE (avg)
14.28%
Valuation key factors
Factor
Value
P/E Ratio
22
Industry P/E
Price to Book Value
2.23
EV to EBIT
18.23
EV to EBITDA
10.30
EV to Capital Employed
1.72
EV to Sales
2.33
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
9.44%
ROE (Latest)
9.99%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 144 Schemes (51.7%)
Foreign Institutions
Held by 313 Foreign Institutions (26.7%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
1,032.10
984.20
4.87%
Operating Profit (PBDIT) excl Other Income
251.80
218.90
15.03%
Interest
30.00
27.90
7.53%
Exceptional Items
-32.20
-23.80
-35.29%
Consolidate Net Profit
52.70
25.90
103.47%
Operating Profit Margin (Excl OI)
128.20%
100.10%
2.81%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 4.87% vs -1.83% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 103.47% vs 112.12% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
4,050.00
4,129.40
-1.92%
Operating Profit (PBDIT) excl Other Income
928.60
975.30
-4.79%
Interest
126.30
136.70
-7.61%
Exceptional Items
-352.40
-43.90
-702.73%
Consolidate Net Profit
25.30
480.40
-94.73%
Operating Profit Margin (Excl OI)
140.00%
160.10%
-2.01%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -1.92% vs 3.86% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -94.73% vs -2.48% in Dec 2023
About Charles River Laboratories International, Inc. 
Charles River Laboratories International, Inc.
Miscellaneous
Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company's clients' manufacturing activities.
Company Coordinates 
Company Details
251 Ballardvale St , WILMINGTON MA : 01887-1096
Registrar Details






